Protection against lethal challenge by Ebola virus-like particles produced in insect cells.
Ebola virus-like particles (VLPs) were produced in insect cells using a recombinant baculovirus expression system and their efficacy for protection against Ebola virus infection was investigated. Two immunizations with 50 microg Ebola VLPs (high dose) induced a high level of antibodies against Ebola GP that exhibited strong neutralizing activity against GP-mediated virus infection and conferred complete protection of vaccinated mice against lethal challenge by a high dose of mouse-adapted Ebola virus. In contrast, two immunizations with 10 microg Ebola VLPs (low dose) induced 5-fold lower levels of antibodies against GP and these mice were not protected against lethal Ebola virus challenge, similar to control mice that were immunized with 50 microg SIV Gag VLPs. However, the antibody responses against GP were boosted significantly after a third immunization with 10 microg Ebola VLPs to similar levels as those induced by two immunizations with 50 microg Ebola VLPs, and vaccinated mice were also effectively protected against lethal Ebola virus challenge. Furthermore, serum viremia levels in protected mice were either below the level of detection or significantly lower compared to the viremia levels in control mice. These results show that effective protection can be achieved by immunization with Ebola VLPs produced in insect cells, which give high production yields, and lend further support to their development as an effective vaccine strategy against Ebola virus.
Sun
Yuliang
Y
Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Room 3086 Rollins Research Center, Atlanta, GA 30322, USA.
Carrion
Ricardo
R
Ye
Ling
L
Wen
Zhiyuan
Z
Ro
Young-Tae
YT
Brasky
Kathleen
K
Ticer
Anysha E
AE
Schwegler
E Ellen
EE
Patterson
Jean L
JL
Compans
Richard W
RW
Yang
Chinglai
C
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D016367:Baculoviridae / Q000235:genetics; D002460:Cell Line; D046129:Ebola Vaccines / Q000276:immunology*; D029043:Ebolavirus / Q000276:immunology*; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology / Q000517:prevention & control*; D007117:Immunization, Secondary; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D018411:Spodoptera; D016019:Survival Analysis; D022721:Vaccines, Virosome / Q000276:immunology; D014766:Viremia / Q000276:immunology / Q000517:prevention & control
D000914:Antibodies, Viral; D046129:Ebola Vaccines; D022721:Vaccines, Virosome